upamostat
Small moleculeexperimental
Upamostat is a drug which acts as an inhibitor of the serine protease enzyme urokinase. It is under development as a potential treatment agent for pancreatic cancer, acting to inhibit tumour metastasis. — Wikipedia
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Apr 1, 2007 (NCT00499265)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Urokinase-type plasminogen activatorINHIBITOR
PLAU inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCOC(=O)N1CCN(C(=O)[C@H](Cc2cccc(/C(N)=N\O)c2)NS(=O)(=O)c2c(C(C)C)cc(C(C)C)cc2C(C)C)CC1- Mol. weight
- 629.82 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaUpamostat ↗
- ChEMBLCHEMBL4206119 ↗
Also known as
- upamostat
- upamostat
- upamostat
- wx-671
- wx-671
- wx-671
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05954286 | Phase 2 | Sep 30, 2023 | FHI Clinical, Inc., Henry M. Jackson Foundation for the Advancement of Military Medicine, RedHill Biopharma |
| NCT04723537 | Phase 2/Phase 3 (Phase 3) | Feb 16, 2021 | RedHill Biopharma |
| NCT00615940 | Phase 2 | Jul 1, 2008 | Temple University, United States Army, Wilex |
| NCT00499265 | Phase 2 | Apr 1, 2007 | Wilex |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| RedHill Biopharma | For profit | 2 | 1 | 2 | 2021 |
| Wilex | For profit | 2 | 2 | 1 | 2007 |
| FHI Clinical, Inc. | For profit | 1 | 0 | 1 | 2023 |
| Henry M. Jackson Foundation for the Advancement of Military Medicine | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Temple University | Academic/Hospital | 1 | 0 | 1 | 2008 |
| United States Army | Government | 1 | 0 | 1 | 2008 |
6 organizations
Page 1 / 1